PRISM evaluates 4D-150, a potential backbone therapy designed to provide multi-year sustained delivery of anti-VEGF ...

D Molecular Therapeutics reported 52-week Phase 2b data for 4D-150 in wet AMD, showing sustained visual acuity improvements.

“OCU200 has the potential to change the treatment landscape for DME, diabetic retinopathy (DR), and wet age-related macular degenerati ... leaders MALVERN, Pa., Oct. 28, 2024 (GLOBE NEWSWIRE ...

Here's what macular degeneration is, what causes it and how you can expect it to be treated if it affects you or a loved one.

This has been shown to delay the vision changes associated with all types of macular degeneration. Unfortunately, aging and family history are risk factors out of our control. Wet macular ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

In this Healio Video Perspective from Retina 2025, Ashkan M. Abbey, MD, discusses 1-year results from the phase 2 DAVIO 2 clinical trial investigating EYP-1901 in previously treated wet age-related ...

Wet age-related macular degeneration threatens central vision when abnormal blood vessels leak fluid in the eye. Treatments can help preserve eyesight but may cost tens of thousands per year.

A unique collaboration between electrical engineers and ophthalmologists solves clinical, computational challenges.

ALPHARETTA, Ga. - Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company with a market capitalization of $85.7 million focused on developing therapies for ocular diseases, has announced ...

In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

Modern Retina - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...